Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 9/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12670786 | 0.86 | ALDH1A1 (0.44) | MAPK14PTGS2CA1CA2CA4 | |
| SCHEMBL12670789 | 0.81 | SLC5A1 (0.49) | PTGS2CA1CA2CA4CA9 | |
| SCHEMBL567752 | 0.81 | CCR1 (0.54) | MAPK14CCR1NR3C1CYP17A1CYP1A2 | |
| SCHEMBL12670787 | 0.80 | NR3C1 (0.46) | MAPK14PTGS2CCR1NR3C1KMT2A | |
| SCHEMBL12670788 | 0.77 | MAPK14 (0.45) | MAPK14CCR1NR3C1KMT2ACYP17A1 | |
| SCHEMBL567998 | 0.76 | CCR1 (0.55) | MAPK14CCR1 | |
| SCHEMBL1880464 | 0.75 | MAPT (0.47) | MAPK14KMT2ACYP17A1CYP1A2 | |
| SCHEMBL1135201 | 0.73 | CCR1 (0.61) | MAPK14CCR1CYP17A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL1136005 | 0.72 | CCR1 (0.60) | MAPK14CCR1CYP17A1CYP1A2 | |
| SCHEMBL12800131 | 0.70 | CCR1 (0.50) | CCR1NR3C1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2493875-B1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2493875-B1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20120270879-A1 | Heterocyclic Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270879-A1 | Heterocyclic Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270879-A1 | Heterocyclic Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2011056440-A1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270879-A1 | Heterocyclic Compounds As CCR1 Receptor Antagonists | CCR1, CCRL2, CCR3 | MAPK14 4297/4885PTGS2 1614/4885CCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.